The Australasian Society of Clinical Immunology and Allergy (ASCIA) is the peak professional body of clinical immunology and allergy specialists in Australia and New Zealand.
The content of ASCIA anaphylaxis e-training for health professionals (HP) has been reviewed by ASCIA members, represents the available published literature at the time of review and is not intended to replace professional medical advice. Any questions regarding a medical diagnosis or treatment should be directed to a medical practitioner.
ASCIA anaphylaxis e-training HP has been developed to provide ready access to reliable and consistent anaphylaxis education for all health professionals throughout Australia and New Zealand, at no charge. Initial funding for development of ASCIA anaphylaxis e-training HP has been obtained from Health Departments of New South Wales and Western Australia, as well as an unrestricted educational grant from Alphapharm. Further funding has been provided by the Health Department of Western Australia to develop the advanced acute management of anaphylaxis module. ASCIA will retain copyright and control over content of ASCIA anaphylaxis e-training, and update it as evidence based changes occur in the medical literature.
Whilst a Certificate of Completion for ASCIA anaphylaxis e-training HP can be provided as proof that training has been successfully completed, the certificate is not a qualification as ASCIA is not an accrediting body. ASCIA anaphylaxis e-training HP is not an anaphylaxis train the trainer course, which needs to be completed through a face to face anaphylaxis train the trainer course.
ASCIA anaphylaxis e-training HP contains information about adrenaline autoinjectors including an optional video instruction guide which has been prepared and copyrighted by supplier of these devices in Australia and New Zealand. The information is provided for general information only, does not in any way constitute medical advice or opinion and is subject to disclaimers issued by the supplier (EpiPen® - www.epiclub.com.au).
Adrenaline autoinjectors must only be used as directed and any questions should be directed to a medical practitioner. The active ingredient in an adrenaline autoinjector is adrenaline and for further information you should refer to the relevant consumer information provided by the supplier of adrenaline autoinjectors. ASCIA anaphylaxis e-training HP contains links to other websites. These linked websites are not under the control of ASCIA and inclusion of any link does not imply endorsement of the linked website by ASCIA.
Any inquiries regarding ASCIA anaphylaxis e-training HP should be emailed to firstname.lastname@example.org
Due to the potential number of inquiries a contact telephone number is not available. For assistance go to Help.
Address inquiries regarding usage of the ASCIA trademarks or copyrights or the trademarks and copyrights of others which are contained in this site to:
Chief Executive Officer
The Australasian Society of Clinical Immunology and Allergy (ASCIA)
PO Box 450 Balgowlah NSW 2093